WallStreetZenWallStreetZen

NASDAQ: SNSE
Sensei Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SNSE stock forecasts and price targets.

Forecast return on equity

Is SNSE forecast to generate an efficient return?

Company
-87.5%
Industry
62.54%
Market
166.28%
SNSE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SNSE forecast to generate an efficient return on assets?

Company
-71.03%
Industry
30.53%
SNSE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SNSE earnings per share forecast

What is SNSE's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.83
Avg 2 year Forecast
-$8.26
Avg 3 year Forecast
-$14.69

SNSE revenue forecast

What is SNSE's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

SNSE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SNSE$26.96N/AN/A
GRCE$2.34$8.00+241.88%Strong Buy
VERU$2.26$25.00+1,006.19%Strong Buy
PTN$20.23$60.00+196.59%Strong Buy
APLM$16.22N/AN/A
View Top Biotech Stocks

Sensei Biotherapeutics Stock Forecast FAQ

What is SNSE's earnings growth forecast for 2026-2028?

(NASDAQ: SNSE) Sensei Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.37%.

Sensei Biotherapeutics's earnings in 2026 is -$21,085,000.On average, 4 Wall Street analysts forecast SNSE's earnings for 2026 to be -$3,786,830, with the lowest SNSE earnings forecast at -$3,638,327, and the highest SNSE earnings forecast at -$3,898,207. On average, 4 Wall Street analysts forecast SNSE's earnings for 2027 to be -$11,073,402, with the lowest SNSE earnings forecast at -$16,326,499, and the highest SNSE earnings forecast at -$5,305,502.

In 2028, SNSE is forecast to generate -$19,686,047 in earnings, with the lowest earnings forecast at -$18,914,045 and the highest earnings forecast at -$20,265,049.

If you're new to stock investing, here's how to buy Sensei Biotherapeutics stock.

What is SNSE's revenue growth forecast for 2026-2028?

(NASDAQ: SNSE) Sensei Biotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Sensei Biotherapeutics's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast SNSE's revenue for 2026 to be $0, with the lowest SNSE revenue forecast at $0, and the highest SNSE revenue forecast at $0. On average, 4 Wall Street analysts forecast SNSE's revenue for 2027 to be $0, with the lowest SNSE revenue forecast at $0, and the highest SNSE revenue forecast at $0.

In 2028, SNSE is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SNSE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SNSE) forecast ROA is -71.03%, which is lower than the forecast US Biotechnology industry average of 30.53%.

What is SNSE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SNSE) Sensei Biotherapeutics's current Earnings Per Share (EPS) is -$16.72. On average, analysts forecast that SNSE's EPS will be -$2.83 for 2026, with the lowest EPS forecast at -$2.71, and the highest EPS forecast at -$2.91. On average, analysts forecast that SNSE's EPS will be -$8.26 for 2027, with the lowest EPS forecast at -$12.18, and the highest EPS forecast at -$3.96. In 2028, SNSE's EPS is forecast to hit -$14.69 (min: -$14.11, max: -$15.12).

What is SNSE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SNSE) forecast ROE is -87.5%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.